Full Text View
Tabular View
No Study Results Posted
Related Studies
Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
This study is currently recruiting participants.
Verified by Cosmetique Active International, September 2009
First Received: July 24, 2009   Last Updated: September 14, 2009   History of Changes
Sponsor: Cosmetique Active International
Collaborator: Innovaderm Research Inc.
Information provided by: Cosmetique Active International
ClinicalTrials.gov Identifier: NCT00974480
  Purpose

Facial skin aging is a complex process combining factors such as sun exposure, smoking and those that are believed to be inherited. Changes in the skin over time including decreased thickness result in skin atrophy, wrinkling, sagging, yellowness and changes in pigmentation. Redermic is a cosmetic cream that has been evaluated clinically but not in comparison to tretinoin nor in combination with tretinoin. There is no data on the safety and efficacy of Redermic as compared to topical tretinoin.

Rejuva is a cream currently approved by Health Canada for the treatment of photodamaged skin. It contains 0.025% tretinoin one of the most widely studied topical product for skin aging. Studies have shown that topical tretinoin increases collagen synthesis and epidermal thickness thereby improving the appearance of skin aging. The efficacy of Rejuva combined with another topical cosmetic cream such as Redermic in the treatment of skin aging is unknown.

One hundred and twenty (120) subjects with signs of skin aging will participate in this single-blind study to evaluate the efficacy and tolerance of Redermic versus Rejuva-A™ (0.025% tretinoin) and Redermic in combination with Rejuva-A™ (0.025% tretinoin).


Condition Intervention
Skin Aging
 Other: Redermic
Drug: Tretinoin (Rejuva-A)

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Investigator), Parallel Assignment, Safety/Efficacy Study
Official Title: Single Blind Study to Evaluate the Tolerance and Effectiveness of Redermic Versus Rejuva-A™ (0.025% Tretinoin) and Redermic in Combination With Rejuva-A™ (0.025% Tretinoin) Under Normal Conditions in Subjects With Signs of Aging

Resource links provided by NLM:

MedlinePlus related topics: Cosmetics Skin Aging
Drug Information available for: Tretinoin
U.S. FDA Resources

Further study details as provided by Cosmetique Active International:

Primary Outcome Measures:
  • Changes from baseline over time in skin aging as measured with the photonumeric scale for subjects randomized to Redermic only [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes from baseline in photographic evaluation by a panel of blinded dermatologists at Week 24 for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in trans-epidermal water loss (TEWL) for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in skin hydration for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in skin elasticity for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in scoring of skin replicas of crow's feet at Week 24 for subjects randomized to Redermic only. [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in facial clinical skin evaluation for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in sensitivity of the face evaluated by subject for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in facial skin self-evaluation for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in facial scaling, dryness, erythema as well as burning and itching for subjects randomized to Redermic only. [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Changes from baseline over time in skin aging as measured with the photonumeric scale for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in photographic evaluation by a panel of blinded dermatologists at Week 24 for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in trans-epidermal water loss (TEWL) for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in skin hydration for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in skin elasticity for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in scoring of skin replicas of crow's feet at Week 24 for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in clinical skin evaluation for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in sensitivity of the face evaluated by subject for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline over time in facial skin self-evaluation for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Cosmetic evaluation scores at Week 12 and Week 24 for Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. (analysis to be performed by La Roche Posay and will not be included in clinical study report). [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Changes from baseline over time in facial scaling, dryness, erythema as well as burning and itching for subjects randomized to Redermic only Redermic compared to Rejuva-A™ or a combination of both Redermic and Rejuva-A™. [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 120
Study Start Date: September 2009
Estimated Study Completion Date: October 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Redermic: Experimental
Cream applied twice a day every day, morning and evening for 24 weeks.
Other: Redermic
Cosmetic cream 609637 43.
Rejuva-A: Active Comparator
Week 1, Rejuva-A cream applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream is applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream is applied to the face in the evening every other day. In cases of intolerance, return to the previous dosage and remain there until the end of study. Neutral cream is applied to the face in the morning every day for 24 weeks.
Drug: Tretinoin (Rejuva-A)
Tretinoin 0.025% cream.
Combination of Redermic and Rejuva-A: Active Comparator
Week 1, Rejuva-A cream applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream is applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream is applied to the face in the evening every other day. In cases of intolerance, return to the previous dosage and remain there until the end of study. Redermic is to be applied every evening when Rejuva-A™ is not applied, as well as every morning.
Other: Redermic
Cosmetic cream 609637 43.
Drug: Tretinoin (Rejuva-A)
Tretinoin 0.025% cream.

Detailed Description:

Facial skin aging is a complex and multifactorial process combining extrinsic and intrinsic factors. Major extrinsic factors include sun exposure and smoking while intrinsic factors are believed to be genetically programmed.

Changes in the dermis are responsible for many of the important clinical changes associated with skin aging. With age there is a decrease in the number of fibroblasts and a decrease in their ability to synthesize collagen which results in a decrease in collagen I and II. This is coupled with an increase in matrix metalloproteinases activity. Skin biopsies from elderly volunteers show changes in collagen bundles which become fragmented and disorganized as well as in elastin fibers which are decreased. Changes also occur in the epidermis including a decrease in epidermal thickness and a change in the morphology of keratinocytes of the basal layer. Clinically these changes result in skin atrophy, increased skin laxity, wrinkling, sagging, yellowness and changes in pigmentation.

Redermic is a cosmetic cream containing vitamin C and madecassoside. A preliminary 20 patient split face study has shown that this product was well tolerated and could improve signs of skin aging. To evaluate changes in skin aging this study used a clinical evaluation of the face, skin hydration, the fringe technique, skin biopsies and skin elasticity measurements. The investigators did not perform TEWL, facial skin evaluation using a photonumeric guideline, evaluation of photoaging by panel of blinded dermatologists or skin replica evaluations. There is no data on the combination of Redermic with tretinoin or on the safety and efficacy of Redermic as compared to topical tretinoin.

Rejuva is a cream currently approved by Health Canada for the treatment of photodamaged skin. It contains 0.025% tretinoin one of the most widely studied topical product for skin aging. Studies have shown that topical tretinoin increases collagen synthesis and epidermal thickness thereby improving the appearance of skin aging. The efficacy of Rejuva combined with another topical cosmetic cream such as Redermic in the treatment of skin aging is unknown.

The main objective of this single-blind study will be to assess efficacy of the anti aging effect and the tolerance of Redermic alone compared to Rejuva-A™ (0.025% tretinoin) alone or in combination with Rejuva-A™ (0.025% tretinoin).

One hundred and twenty (120) subjects with signs of skin aging will participate in this single-blind study to evaluate the efficacy and tolerance of Redermic versus Rejuva-A™ (0.025% tretinoin) and Redermic in combination with Rejuva-A™ (0.025% tretinoin). Subjects will be randomized (1:1:1) in three groups of forty (40), and will be asked to apply study product to the face (except to eyelids, nostrils and other mucous membranes) for 24 weeks.

  Eligibility

Ages Eligible for Study:   45 Years to 55 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects are female, between 45 and 55 years of age.
  • Females of childbearing potential have had a negative urine pregnancy test prior to randomization.
  • Subjects are willing to use adequate contraceptive method or are surgically sterile (including tubal ligation), post-menopausal, abstinent or with a same-sex partner. Adequate means of contraception include; IUD in use for 30 days before Day 0, barrier methods and spermicide in use at least 14 days before Day 0 or oral contraceptive in use for at least 30 days before Day 0.
  • Subjects are willing to avoid prolonged exposure to UV radiation for the duration of the study.
  • Subjects are capable of giving written informed consent.
  • Subjects have changes associated with facial skin aging/photodamaged skin.

Exclusion Criteria:

  • Subjects are male.
  • Subjects are pregnant or lactating.
  • Subjects have a known allergy to Redermic, Rejuva-A™ or to any component of the tested products.
  • Subjects have made use of tretinoin, adapalene, tazarotene or other topical medications for the treatment of facial skin aging during the 12 weeks preceding Day 0.
  • Subjects have applied topical alpha hydroxyl acids within 28 days of Day 0.
  • Subjects have used or plan to use systemic corticosteroids within 28 days of Day 0 or during the study.
  • Subjects have made use of a non-medication topical product directed at improving skin aging during the 28 days preceding Day 0.
  • Subjects have a hypersensitivity to any retinoids.
  • Subjects have a history of alcohol or drug abuse in the past year.
  • Subjects are participating in another interventional study.
  • Subjects have had a previous intense pulsed light treatment to the face.
  • Subjects have had a previous laser treatment to the face directed at improving skin aging.
  • Subjects have the presence of skin diseases such as psoriasis or dermatitis on the face that could interfere with study evaluations.
  • Planned or unavoidable exposure to intense UV radiation during the study (such as sun tanning salons, vacations in a sunny climate or outdoor worker).
  • Subjects have had a botulinum toxin A injection treatment on the face within 2 years of Day 0 or plan to receive this treatment during the study.
  • Subjects have had a filler injection (collagen, hyaluronic acid, etc..) on the face within 2 years of Day 0 or plan to receive this treatment during the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00974480

Locations
Canada, Quebec
Innovaderm Research Inc Recruiting
Montreal, Quebec, Canada, H2K 4L5
Contact: Robert Bissonnette, MD, FRCPC     514 521-4285 ext 210     rbissonnette@innovaderm.ca    
Contact: Frederic Couture     514 521-4285 ext 264     fcouture@innovaderm.ca    
Principal Investigator: Robert Bissonnette, MD, FRCPC            
Sponsors and Collaborators
Cosmetique Active International
Innovaderm Research Inc.
Investigators
Principal Investigator: Robert Bissonnette, MD, FRCPC Innovaderm Research
  More Information

No publications provided

Responsible Party: Innovaderm Research Inc ( Robert Bissonnette, MD, FRCPC )
Study ID Numbers: LRP09008
Study First Received: July 24, 2009
Last Updated: September 14, 2009
ClinicalTrials.gov Identifier: NCT00974480     History of Changes
Health Authority: Canada: Ethics Review Committee

Keywords provided by Cosmetique Active International:
Skin
Aging
Rejuva-a
Redermic

Additional relevant MeSH terms:
Keratolytic Agents
Antineoplastic Agents
Therapeutic Uses
 Tretinoin
Dermatologic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services